Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Clin Pharmacol Ther ; 55(5): 449-452, 2017 May.
Artigo em Inglês | MEDLINE | ID: mdl-28157069

RESUMO

OBJECTIVE: Timely dose reduction of concomitant medications is important after withdrawal of rifampicin, a CYP inducer. However, little is known about the differences in the time course of deinduction for various CYP isoforms. To clarify the time courses of deinduction of CYP2C9 and -CYP3A activities after rifampicin withdrawal, we monitored these enzyme activities in 2 patients over time after discontinuing rifampicin. MATERIALS AND METHODS: Two patients (aged 70 and 80 years) received warfarin and rifampicin for anticoagulation and antituberculosis therapy, respectively. Warfarin doses were increased due to rifampicin-induced CYP activity. Upon completion of antituberculosis therapy, rifampicin was discontinued and warfarin doses were titrated downward according to prothrombin time. We monitored CYP2C9 and CYP3A activities over their clinical courses by measuring the metabolic clearance of S-warfarin to S-7-hydroxywarfarin and that of cortisol to 6ß-hydroxycortisol, respectively. RESULTS: In both patients, the time courses of CYP2C9 deinduction appeared to be delayed compared to CYP3A. CONCLUSION: Our findings suggest that a uniform dose reduction protocol for drugs metabolized by different CYP isoforms may be unsafe after rifampicin withdrawal.
.


Assuntos
Antibióticos Antituberculose/efeitos adversos , Anticoagulantes/administração & dosagem , Indutores do Citocromo P-450 CYP2C9/efeitos adversos , Citocromo P-450 CYP2C9/biossíntese , Indutores do Citocromo P-450 CYP3A/efeitos adversos , Citocromo P-450 CYP3A/biossíntese , Rifampina/efeitos adversos , Varfarina/administração & dosagem , Idoso , Idoso de 80 Anos ou mais , Antibióticos Antituberculose/administração & dosagem , Anticoagulantes/efeitos adversos , Anticoagulantes/farmacocinética , Coagulação Sanguínea/efeitos dos fármacos , Indutores do Citocromo P-450 CYP2C9/administração & dosagem , Indutores do Citocromo P-450 CYP3A/administração & dosagem , Cálculos da Dosagem de Medicamento , Interações Medicamentosas , Monitoramento de Medicamentos/métodos , Indução Enzimática , Feminino , Humanos , Coeficiente Internacional Normatizado , Polimedicação , Tempo de Protrombina , Rifampina/administração & dosagem , Especificidade por Substrato , Varfarina/efeitos adversos , Varfarina/farmacocinética
2.
Acta Neurol Taiwan ; 24(2): 43-6, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26179835

RESUMO

PURPOSE: To report the unsafe herb-drug interactions between a commercial product of noni juice and phenytoin in a human case. CASE REPORT: A 49-year-old-male has been treated with phenytoin for epilepsy for more than ten years. In spite of his medication adherence, persistent sub-therapeutic phenytoin levels, which were sometimes from low to undetectable, with the result of having poor seizure control were noted as the noni fruit juice was co-administered daily. The possible mechanism is speculated to be due to noni juiceinduced cytochrome P-450 2C9 metabolism of phenytoin. Owing to many beneficial effects of noni juice, the patient was unwilling to accept our advice to quit taking it. Clobazam treatment was added, and with gradually reducing the amount of juice drunk over six months, the patient's epilepsy has been well controlled. Now only auras along with sometimes minor partial seizures occur, but no major attack has been reported for more than one year. CONCLUSION: Phenytoin had been commonly used for seizure control worldwide and nearly half of patients with epilepsy had received complementary and alternative medicine in Taiwan. Thus, this report is significantly important for clinicians to be aware of the interaction between antiepileptic drugs and some herbs like noni juice. Moreover, as far as we know, this is a rare human case that is reported to disclose this unfavorable herb-drug interaction.


Assuntos
Indutores do Citocromo P-450 CYP1A2/farmacologia , Indutores do Citocromo P-450 CYP2C9/efeitos adversos , Epilepsia/tratamento farmacológico , Sucos de Frutas e Vegetais/efeitos adversos , Interações Ervas-Drogas , Morinda/efeitos adversos , Fenitoína/farmacologia , Indutores do Citocromo P-450 CYP1A2/administração & dosagem , Epilepsia/induzido quimicamente , Humanos , Masculino , Pessoa de Meia-Idade , Fenitoína/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...